NCT00048945CompletedPhase 3
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 820
- Locations
- 74
Study Overview
Brief Summary
The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Clinical diagnosis of hepatitis B
- •Not pregnant
Exclusion Criteria
- •Treatment for hepatitis B in past 6 months
- •Other hepatitis infections
- •Severe liver disease
- •Pregnancy
Investigators
Study Sites (74)
Loading locations...
Similar Trials
Completed
Phase 4
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infectionHepatitis C, ChronicNCT00353418Hoffmann-La Roche415
Terminated
Phase 4
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.Hepatitis B, ChronicNCT00460850Hoffmann-La Roche60
Completed
Phase 4
Trial of Pegasys® in Patients With Chronic Hepatitis CChronic Hepatitis CNCT00245414Chugai Pharmaceutical108
Completed
Phase 4
Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.Hepatitis C, ChronicNCT00107653Hoffmann-La Roche569
Completed
Phase 4
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis BHepatitis B, ChronicNCT00922207Hoffmann-La Roche280